GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Ending Cash Position

Mereo BioPharma Group (Mereo BioPharma Group) Ending Cash Position : $57.42 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Ending Cash Position?

Mereo BioPharma Group's Ending Cash Position for the quarter that ended in Dec. 2023 was $57.42 Mil.

Mereo BioPharma Group's quarterly Ending Cash Position declined from Dec. 2022 ($68.18 Mil) to Jun. 2023 ($53.12 Mil) but then increased from Jun. 2023 ($53.12 Mil) to Dec. 2023 ($57.42 Mil).

Mereo BioPharma Group's annual Ending Cash Position declined from Dec. 2021 ($127.27 Mil) to Dec. 2022 ($68.18 Mil) and declined from Dec. 2022 ($68.18 Mil) to Dec. 2023 ($57.42 Mil).


Mereo BioPharma Group Ending Cash Position Historical Data

The historical data trend for Mereo BioPharma Group's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Ending Cash Position Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 21.43 31.98 127.27 68.18 57.42

Mereo BioPharma Group Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.27 92.68 68.18 53.12 57.42

Mereo BioPharma Group Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Mereo BioPharma Group's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=68.181+-10.76
=57.42

Mereo BioPharma Group's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=50.245+7.176
=57.42


Mereo BioPharma Group Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (Mereo BioPharma Group) Headlines

From GuruFocus